NCT01156571

A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)

A Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention (CHAMPION PHOENIX)

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 11,145 (actual)
• Sponsor: The Medicines Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The study is designed to compare the efficacy and safety profile of cangrelor to standard of care in patients require percutaneous coronary intervention (PCI).

Conditions

• Atherosclerosis
• Percutaneous Coronary Intervention
• Acute Coronary Syndrome

Interventions

Type	Name	Description
DRUG	cangrelor P2Y12 (platelet) inhibitor
DRUG	Clopidogrel - 300 or 600 mg (study arm)	Over encapsulated tablets.
DRUG	Clopidogrel 600 mg post cangrelor	over-encapsulated clopidogrel (600 mg)

Timeline

• Start date: 2010-09-01
• Primary completion: 2012-12-01
• Completion: 2012-12-01
• First posted: 2010-07-05
• Last updated: 2014-02-04
• Results posted: 2013-06-18

Locations

1 site across 1 country: United States